Makary Defends FDA’s Decision-Making Amid Contentious Rare Disease Rejections

Without naming a specific product, Commissioner Marty Makary referred to an investigational therapy, delivered surgically into the brain, that the FDA was “pressured” to approve even after finding no clinical benefit to patients.

Scroll to Top